Biotech Values

[jbog]

Juno Therapeutics, Celgene, Acquired by GILD 9/17, Gilead analyst commentary at Citi Juno could be worth $110 per share in takeover, says Citi. After the Wall Street Journal reported tonight that Celgene (CELG) is in talks to acquire Juno Therapeutics (JUNO), Citi analyst Robyn Karnauskas says her analysis indicates Juno could be worth $110 per share in a takeover. The stock in after-hours trading jumped 43%, or $19.50, to $65.10. The analyst, however, points that Kite Pharma had more data at the time of acquisition and was acquired by Gilead Sciences (GILD) for an aggregate price of $11.9B. Karnauskas also notes that Celgene already downs 25% of June's revenues
Read more at:
https://thefly.com/landingPageNews.php?id=2667687

Seems Silly, but it's better than Bitcoin.